Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.

“We are thrilled to be selected for an oral presentation at ADA to highlight additional data from the 28-day Phase 1 study of TERN-601 demonstrating its differentiated profile among oral GLP1-R ...

--Wave Life Sciences Ltd., a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of ...